Alzheimers
-
Pharma Flop: Eli Lilly's Alzheimer Cure Fails Drug Trials
Eli Lilly and Co.’s promising pharmaceutical drug for memory-fading disease, Alzheimer’s, has failed its large clinical trial. According to the company’s official statement, patients treated with solanezumab did not experience a statistically significant slowing in cognitive decline compared to patients treated with placebo.
Latest Research Articles
-
BEWARE: Why Loneliness Could be a Behavioral Symptom of Preclinical Alzheimer's Disease
-
New Merck Drug May Be the Cure for Alzheimer's Disease
-
Shocking! Toxic Pollution Particles Found in Human Brain for the First Time, Alzheimer's Explained
-
Study: How Electric Brain Simulation During Sleep Improve Memory
-
Certain Molecule in Red Wine, Chocolates Could Help Slow Down Symptoms of Alzheimer's
-
HIV Update: Researchers Report First Case of HIV-Patient Diagnosed with Dementia
-
Color Blindness: New Cause Identified
-
Amnesia: 'Lost' Memories in Mice Retrieved with Light
-
Alzheimer's Affects Far More Women Than Men, and Here's Why
-
MIND Diet May Protect Against Alzheimer's
-
Memory Loss Much Faster in Men Than Women
-
New Drug Approach May Delay Alzheimer's Dementia
most popular
-
Arctic Temperature Slowdown May Curb Arctic Warming by 2°C, But Risks Remain
-
Important Role Satellites Play in Weather Forecasting, Monitoring Hurricanes
-
7 Effective Strategies to Ward Off Winter Illnesses
-
Eco-Friendly Travel Tips for Visiting Tempe, AZ: Explore Sustainably
-
How Do Moon Phases Affect the Earth?
